18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size

被引:45
作者
Ciarmiello, Andrea [1 ]
Giovacchini, Giampiero [1 ]
Orobello, Sara [2 ]
Bruselli, Laura [1 ]
Elifani, Francesca [2 ]
Squitieri, Ferdinando [2 ]
机构
[1] S Andrea Hosp, Dept Nucl Med, La Spezia, Italy
[2] IRCCS Neuromed, Ctr Neurogenet & Rare Dis, Pozzilli, IS, Italy
关键词
F-18-FDG PET scan; Caudate glucose metabolism; Age at onset prediction; Phenoconversion; AGE-OF-ONSET; GLUCOSE-METABOLISM; BRAIN; INDIVIDUALS; PREDICTION; BIOMARKERS; MUTATION; NEURONS; ATROPHY; REPEAT;
D O I
10.1007/s00259-012-2114-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
To test in a longitudinal follow-up study whether basal glucose metabolism in subjects with a genetic risk of Huntington disease (HD) may influence the onset of manifest symptoms. The study group comprised 43 presymptomatic (preHD) subjects carrying the HD mutation. They underwent a F-18-FDG PET scan and were prospectively followed-up for at least 5 years using the unified HD rating scale to detect clinical changes. Multiple regression analysis included subject's age, CAG mutation size and glucose uptake as variables in a model to predict age at onset. Of the 43 preHD subjects who manifested motor symptoms, suggestive of HD, after 5 years from the PET scan, 26 showed a mean brain glucose uptake below the cut-off of 1.0493 in the caudate, significantly lower than the 17 preHD subjects who remained symptom-free (P < 0.0001). This difference was independent of mutation size. Measurement of brain glucose uptake improved the CAG repeat number and age-based model for predicting age at onset by 37 %. A reduced level of glucose metabolism in the brain caudate may represent a predisposing factor that contributes to the age at onset of HD in preHD subjects, in addition to the mutation size.
引用
收藏
页码:1030 / 1036
页数:7
相关论文
共 38 条
[1]   Unsupervised, automated segmentation of the normal brain using a multispectral relaxometric magnetic resonance approach [J].
Alfano, B ;
Brunetti, A ;
Covelli, EM ;
Quarantelli, M ;
Panico, MR ;
Ciarmiello, A ;
Salvatore, M .
MAGNETIC RESONANCE IN MEDICINE, 1997, 37 (01) :84-93
[2]   Striatal glucose metabolism and dopamine D-2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease [J].
Antonini, A ;
Leenders, KL ;
Spiegel, R ;
Meier, D ;
Vontobel, P ;
WeigellWeber, M ;
SanchezPernaute, R ;
deYebenez, JG ;
Boesiger, P ;
Weindl, A ;
Maguire, RP .
BRAIN, 1996, 119 :2085-2095
[3]   Onset and rate of striatal atrophy in preclinical Huntington disease [J].
Aylward, EH ;
Sparks, BF ;
Field, KM ;
Yallapragada, V ;
Shpritz, BD ;
Rosenblatt, A ;
Brandt, J ;
Gourley, LM ;
Liang, K ;
Zhou, H ;
Margolis, RL ;
Ross, CA .
NEUROLOGY, 2004, 63 (01) :66-72
[4]   Early defect of transforming growth factor β1 formation in Huntington's disease [J].
Battaglia, Giuseppe ;
Cannella, Milena ;
Riozzi, Barbara ;
Orobello, Sara ;
Maat-Schieman, Marion L. ;
Aronica, Eleonora ;
Busceti, Carla Letizia ;
Ciarmiello, Andrea ;
Alberti, Silvia ;
Amico, Enrico ;
Sassone, Jenny ;
Sipione, Simonetta ;
Bruno, Valeria ;
Frati, Luigi ;
Nicoletti, Ferdinando ;
Squitieri, Ferdinando .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2011, 15 (03) :555-571
[5]   Striatal size, glucose metabolic rate, and verbal learning in normal aging [J].
Brickman, AM ;
Buchsbaum, MS ;
Shihabuddin, L ;
Hazlett, EA ;
Borod, JC ;
Mohs, RC .
COGNITIVE BRAIN RESEARCH, 2003, 17 (01) :106-116
[6]  
Brinkman RR, 1997, AM J HUM GENET, V60, P1202
[7]   DNA instability in replicating Huntington's disease lymphoblasts [J].
Cannella, Milena ;
Maglione, Vittorio ;
Martino, Tiziana ;
Ragona, Giuseppe ;
Frati, Luigi ;
Li, Guo-Min ;
Squitieri, Ferdinando .
BMC MEDICAL GENETICS, 2009, 10
[8]  
Ciarmiello A, 2006, J NUCL MED, V47, P215
[9]   Seeking Brain Biomarkers for Preventive Therapy in Huntington Disease [J].
Esmaeilzadeh, Mouna ;
Ciarmiello, Andrea ;
Squitieri, Ferdinando .
CNS NEUROSCIENCE & THERAPEUTICS, 2011, 17 (05) :368-386
[10]   Metabolic correlates of levodopa response in Parkinson's disease [J].
Feigin, A ;
Fukuda, M ;
Dhawan, V ;
Przedborski, S ;
Jackson-Lewis, V ;
Mentis, MJ ;
Moeller, JR ;
Eidelberg, D .
NEUROLOGY, 2001, 57 (11) :2083-2088